YM Bio Heads South of the Border in Good Way (YMI)

Posted in pre-market 
September 17th, 2009

YM BioSciences Inc. (AMEX: YMI) is up pretty big considering its low volume status.  The company said that its nimotuzumab has been approved for marketing in Mexico for the treatment of squamous cell carcinoma of the head and neck, adult glioma and pediatric glioma. Nimotuzumab will be commercialized under the name VECTHIXYM BioSciences also announces that it has enrolled the first two patients in its randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from non-small-cell lung cancer. At 8:46 AM EST we have shares up 19% at $1.85 on 131,000 shares.  The 52-week high is only $2.24 and this trades about 600,000 shares on an average day. -JON OGG

Comments are closed

-->